Imunon Sells ThermoDox to VoxelDox for 4.76% Equity, Up to $16.5M Milestones
IMNN is trading near its 52-week low of $0.96 (11% above the low).
Summary
Imunon agreed to sell its written-off ThermoDox asset to VoxelDox for a 4.76% equity stake, up to $16.5M in milestones and 3.5%-6% royalties, contingent on VoxelDox first raising $2.5M. No cash changes hands at signing, and the deal lets Imunon focus spending on its Phase 3 IMNN-001 program.
Key Events · M&A and Partnerships · IMNN
-
ThermoDox Sold to VoxelDox
An Asset Purchase Agreement dated October 20, 2026 transfers ThermoDox trademarks, regulatory filings, clinical and preclinical data, manufacturing know-how and existing drug vials to VoxelDox Therapeutics.
-
Contingent Consideration, No Upfront Cash
Imunon gets 4.76% of VoxelDox fully diluted equity, up to $16.5M in clinical and regulatory milestones, and tiered royalties of 3.5% to 6% on net sales. No cash is paid at signing.
-
Closing Hinges on $2.5M Raise
The deal will not close and Imunon receives no consideration unless VoxelDox raises at least $2.5M to fund a Phase 1 glioblastoma trial. Milestones and royalties are halved if the transferred vials are deemed unusable.
-
Insiders to Receive VoxelDox Stock
Subject to VoxelDox board approval, Executive Chairman Michael Tardugno and director Frederick Fritz will each receive VoxelDox shares equal to 2.38% of its fully diluted capitalization, vesting monthly over 36 months, for consulting services.
Analysis · IMNN · Life Sciences
Imunon is offloading a legacy asset that has already been fully written off, so there is no book-value hit, and it gets a small equity stake plus contingent milestones and 3.5%-6% royalties if VoxelDox can develop ThermoDox for glioblastoma. The near-term cash is zero: closing depends on VoxelDox raising at least $2.5M, and if that fails Imunon receives nothing. The real value is strategic — it clears management's attention and resources for the Phase 3 OVATION 3 trial of IMNN-001, which is the program that matters, against a backdrop of a going-concern warning and $6.9M in cash reported in August. Note the related-party element: Executive Chairman Michael Tardugno and director Frederick Fritz are slated to receive VoxelDox stock equal to 2.38% of its fully diluted capitalization each for consulting work.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 29.1% of the 1524 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMNN was trading at $1.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6M. The 52-week trading range was $0.96 to $5.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.